JP2019515043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515043A5 JP2019515043A5 JP2019510575A JP2019510575A JP2019515043A5 JP 2019515043 A5 JP2019515043 A5 JP 2019515043A5 JP 2019510575 A JP2019510575 A JP 2019510575A JP 2019510575 A JP2019510575 A JP 2019510575A JP 2019515043 A5 JP2019515043 A5 JP 2019515043A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- independently
- och
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 77
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 125000004429 atom Chemical group 0.000 claims description 16
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- -1 pyridazinonyl Chemical group 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 230000004770 neurodegeneration Effects 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 208000036546 leukodystrophy Diseases 0.000 claims description 5
- 201000006938 muscular dystrophy Diseases 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000004306 triazinyl group Chemical group 0.000 claims description 5
- 125000001425 triazolyl group Chemical group 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 4
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000000585 muscular atrophy Diseases 0.000 claims description 4
- 208000017445 musculoskeletal system disease Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 claims description 3
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 claims description 3
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims description 3
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 210000004885 white matter Anatomy 0.000 claims description 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 102000007371 Ataxin-3 Human genes 0.000 claims description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010011777 Cystinosis Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 102000006386 Myelin Proteins Human genes 0.000 claims description 2
- 108010083674 Myelin Proteins Proteins 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011252 Phenylketonuria Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000013507 chronic prostatitis Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 2
- 230000008602 contraction Effects 0.000 claims description 2
- 201000009338 distal myopathy Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 210000003000 inclusion body Anatomy 0.000 claims description 2
- 206010023497 kuru Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000022084 motor paralysis Diseases 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 210000005012 myelin Anatomy 0.000 claims description 2
- 230000003274 myotonic effect Effects 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000001076 sarcopenia Diseases 0.000 claims description 2
- 210000002955 secretory cell Anatomy 0.000 claims description 2
- 208000018198 spasticity Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010006542 Bulbar palsy Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010067601 Dysmyelination Diseases 0.000 claims 1
- 102100034239 Emerin Human genes 0.000 claims 1
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 claims 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 7
- 125000004474 heteroalkylene group Chemical group 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000031736 central nervous system myelination Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021204755A JP7389786B2 (ja) | 2016-05-05 | 2021-12-17 | 統合的ストレス経路のモジュレーター |
| JP2023195552A JP7755632B2 (ja) | 2016-05-05 | 2023-11-17 | 統合的ストレス経路のモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332278P | 2016-05-05 | 2016-05-05 | |
| US62/332,278 | 2016-05-05 | ||
| PCT/US2017/031360 WO2017193034A1 (en) | 2016-05-05 | 2017-05-05 | Modulators of the integrated stress pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204755A Division JP7389786B2 (ja) | 2016-05-05 | 2021-12-17 | 統合的ストレス経路のモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515043A JP2019515043A (ja) | 2019-06-06 |
| JP2019515043A5 true JP2019515043A5 (enExample) | 2020-06-25 |
| JP6997766B2 JP6997766B2 (ja) | 2022-01-20 |
Family
ID=58709639
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510575A Active JP6997766B2 (ja) | 2016-05-05 | 2017-05-05 | 統合的ストレス経路のモジュレーター |
| JP2021204755A Active JP7389786B2 (ja) | 2016-05-05 | 2021-12-17 | 統合的ストレス経路のモジュレーター |
| JP2023195552A Active JP7755632B2 (ja) | 2016-05-05 | 2023-11-17 | 統合的ストレス経路のモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204755A Active JP7389786B2 (ja) | 2016-05-05 | 2021-12-17 | 統合的ストレス経路のモジュレーター |
| JP2023195552A Active JP7755632B2 (ja) | 2016-05-05 | 2023-11-17 | 統合的ストレス経路のモジュレーター |
Country Status (38)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020522553A (ja) * | 2017-06-07 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化合物 |
| US20210145771A1 (en) * | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CN111094233B (zh) | 2017-08-09 | 2024-03-15 | 戴纳立制药公司 | 化合物、组合物及方法 |
| PT3676297T (pt) | 2017-09-01 | 2023-08-29 | Denali Therapeutics Inc | Compostos, composições e métodos |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| RU2020122711A (ru) * | 2017-12-13 | 2022-01-17 | ПРАКСИС БАЙОТЕК ЭлЭлСи | Ингибиторы пути интегрированной реакции на стресс |
| US20210130308A1 (en) * | 2018-03-23 | 2021-05-06 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| SG11202011014VA (en) | 2018-06-05 | 2020-12-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| JP2021529814A (ja) * | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化学化合物 |
| TWI832295B (zh) * | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| CA3129609A1 (en) * | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
| KR20210134351A (ko) * | 2019-02-25 | 2021-11-09 | 프락시스 바이오테크 엘엘씨 | 통합 스트레스 반응 경로의 억제제 |
| EA202192900A1 (ru) | 2019-04-23 | 2022-03-18 | Эвотек Интернешнл Гмбх | Модуляторы пути интегрированной реакции на стресс |
| AU2020261234A1 (en) | 2019-04-23 | 2021-11-11 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| AU2020266592A1 (en) * | 2019-04-30 | 2021-12-02 | Abbvie Inc. | Substituted cyclolakyls as modulators of the integrated stress pathway |
| PH12021552759A1 (en) * | 2019-04-30 | 2022-07-04 | Abbvie Inc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| PH12022551379A1 (en) * | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| KR20220133252A (ko) | 2020-01-28 | 2022-10-04 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절자 |
| JP2023517944A (ja) | 2020-03-11 | 2023-04-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| AU2021366303A1 (en) | 2020-10-22 | 2023-06-22 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| JP2023553149A (ja) * | 2020-12-10 | 2023-12-20 | アジェロ・バイオファーマシューティカルズ・ホールディングス・インコーポレイテッド | 皮膚転移性がんを治療する方法 |
| KR20250122004A (ko) * | 2024-02-05 | 2025-08-13 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 eIF2B 작용제 및 이를 포함하는 대사질환 예방 또는 치료용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US162A (en) | 1837-04-17 | Island | ||
| US5212A (en) | 1847-07-31 | Richard m | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| JP2007517868A (ja) | 2004-01-07 | 2007-07-05 | アストラゼネカ アクチボラグ | 治療薬ｉ |
| GB0400196D0 (en) * | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
| AU2005267093B2 (en) | 2004-07-23 | 2009-10-01 | Nuada Llc | Peptidase inhibitors |
| GB0516314D0 (en) * | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Compound |
| RU2442771C2 (ru) * | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| WO2007017752A1 (en) * | 2005-08-10 | 2007-02-15 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| MX2010003249A (es) * | 2007-09-25 | 2010-11-09 | Takeda Pharmaceutical | Inhibidores de quinasas símil polo. |
| US8741894B2 (en) * | 2010-03-17 | 2014-06-03 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide CCR3 antagonists |
| CN103025725B (zh) | 2010-08-10 | 2015-09-16 | 安斯泰来制药有限公司 | 杂环化合物 |
| AR084457A1 (es) * | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| AU2014233520B2 (en) * | 2013-03-15 | 2019-02-21 | The Regents Of The University Of California | Modulators of the eIF2alpha pathway |
| WO2015038778A1 (en) * | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
| EP3489232A3 (en) * | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
-
2017
- 2017-05-04 TW TW113116736A patent/TW202506629A/zh unknown
- 2017-05-04 TW TW106114859A patent/TWI763668B/zh active
- 2017-05-04 TW TW111113522A patent/TWI844006B/zh active
- 2017-05-05 RS RS20240199A patent/RS65214B1/sr unknown
- 2017-05-05 EP EP17723899.5A patent/EP3452448B1/en active Active
- 2017-05-05 EP EP23213609.3A patent/EP4356971A3/en active Pending
- 2017-05-05 SM SM20240098T patent/SMT202400098T1/it unknown
- 2017-05-05 CN CN201780042069.2A patent/CN109641844B/zh active Active
- 2017-05-05 MX MX2018013495A patent/MX383652B/es unknown
- 2017-05-05 PE PE2023001939A patent/PE20231935A1/es unknown
- 2017-05-05 KR KR1020187035249A patent/KR102512049B1/ko active Active
- 2017-05-05 PE PE2018002316A patent/PE20190348A1/es unknown
- 2017-05-05 SG SG11201809695TA patent/SG11201809695TA/en unknown
- 2017-05-05 JP JP2019510575A patent/JP6997766B2/ja active Active
- 2017-05-05 CR CR20210372A patent/CR20210372A/es unknown
- 2017-05-05 HR HRP20240218TT patent/HRP20240218T1/hr unknown
- 2017-05-05 RU RU2022106770A patent/RU2022106770A/ru unknown
- 2017-05-05 MX MX2021007146A patent/MX2021007146A/es unknown
- 2017-05-05 UY UY0001037228A patent/UY37228A/es active IP Right Grant
- 2017-05-05 LT LTEPPCT/US2017/031360T patent/LT3452448T/lt unknown
- 2017-05-05 ES ES17723899T patent/ES2973442T3/es active Active
- 2017-05-05 SI SI201731474T patent/SI3452448T1/sl unknown
- 2017-05-05 RU RU2018142740A patent/RU2769327C2/ru active
- 2017-05-05 PT PT177238995T patent/PT3452448T/pt unknown
- 2017-05-05 MD MDE20190301T patent/MD3452448T2/ro unknown
- 2017-05-05 MY MYPI2018001857A patent/MY200943A/en unknown
- 2017-05-05 WO PCT/US2017/031360 patent/WO2017193034A1/en not_active Ceased
- 2017-05-05 CA CA3023162A patent/CA3023162A1/en active Pending
- 2017-05-05 CN CN202211242583.XA patent/CN115947681B/zh active Active
- 2017-05-05 DK DK17723899.5T patent/DK3452448T3/da active
- 2017-05-05 BR BR112018072663-0A patent/BR112018072663A2/pt not_active Application Discontinuation
- 2017-05-05 KR KR1020257007932A patent/KR20250042188A/ko active Pending
- 2017-05-05 UA UAA201812001A patent/UA125513C2/uk unknown
- 2017-05-05 MA MA44861A patent/MA44861B1/fr unknown
- 2017-05-05 KR KR1020237009107A patent/KR102781404B1/ko active Active
- 2017-05-05 PH PH1/2018/502329A patent/PH12018502329B1/en unknown
- 2017-05-05 AR ARP170101183A patent/AR110599A1/es unknown
- 2017-05-05 CR CR20180574A patent/CR20180574A/es unknown
- 2017-05-05 FI FIEP17723899.5T patent/FI3452448T3/fi active
- 2017-05-05 AU AU2017260367A patent/AU2017260367B2/en active Active
- 2017-05-05 PL PL17723899.5T patent/PL3452448T3/pl unknown
- 2017-05-05 US US16/098,675 patent/US20190144440A1/en not_active Abandoned
- 2017-05-05 HU HUE17723899A patent/HUE065713T2/hu unknown
-
2018
- 2018-11-01 IL IL262722A patent/IL262722B/en unknown
- 2018-11-02 DO DO2018000242A patent/DOP2018000242A/es unknown
- 2018-11-05 CL CL2018003142A patent/CL2018003142A1/es unknown
- 2018-11-29 CO CONC2018/0012946A patent/CO2018012946A2/es unknown
- 2018-11-30 EC ECSENADI201889579A patent/ECSP18089579A/es unknown
-
2020
- 2020-11-24 US US17/103,003 patent/US20220363678A1/en not_active Abandoned
-
2021
- 2021-09-26 IL IL286693A patent/IL286693B1/en unknown
- 2021-12-17 JP JP2021204755A patent/JP7389786B2/ja active Active
-
2022
- 2022-02-11 AU AU2022200946A patent/AU2022200946B2/en active Active
-
2023
- 2023-11-17 JP JP2023195552A patent/JP7755632B2/ja active Active
-
2024
- 2024-04-26 US US18/648,195 patent/US20250122188A1/en active Pending
- 2024-10-22 AU AU2024227527A patent/AU2024227527A1/en active Pending
-
2025
- 2025-10-09 IL IL323840A patent/IL323840A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515043A5 (enExample) | ||
| JP2019519599A5 (enExample) | ||
| JP2019515042A5 (enExample) | ||
| JP2019530649A5 (enExample) | ||
| RU2018142740A (ru) | Модуляторы интегрированного сигнального пути стресса | |
| AU2019217320B2 (en) | Steroid derivative regulators, method for preparing the same, and uses thereof | |
| JP2019163290A5 (enExample) | ||
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| AU2015337607B2 (en) | Substituted dihydropyrrolopyrazole compound | |
| JP2019508407A5 (enExample) | ||
| PH12020500127A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| JP2013525433A5 (enExample) | ||
| CN114729044B (zh) | 毒蕈碱型乙酰胆碱m1受体拮抗剂 | |
| HRP20230518T1 (hr) | Heteroarilfenoksibenzamidni opioidni ligandi kapa | |
| JP2016510758A5 (enExample) | ||
| JP2013536259A5 (enExample) | ||
| WO2015101928A1 (en) | Fused thiophene and thiazole derivatives as ror gamma modulators | |
| CA2797663A1 (en) | Compounds that modulate intracellular calcium | |
| JP2013530236A5 (enExample) | ||
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| JP2021508318A5 (enExample) | ||
| CN110770233A (zh) | 稠合双环类化合物及其在药物中的应用 | |
| JP2017538712A5 (enExample) | ||
| HRP20211151T1 (hr) | Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama | |
| TW200745135A (en) | Therapeutic agents |